Literature DB >> 17417785

High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia.

Manfred Hensel1, Martin Zoz, Christian Giesecke, Axel Benner, Kai Neben, Anna Jauch, Stephan Stilgenbauer, Anthony D Ho, Alwin Krämer.   

Abstract

B-cell chronic lymphocytic leukemia (CLL) is characterized by a high rate of clonal genomic alterations and a low proliferative activity with cell cycle arrest in G(0)/G(1) phase. Recently, centrosome aberrations have been described as a possible cause of chromosomal instability and aneuploidy in many human malignancies. To investigate whether centrosome aberrations do occur in CLL and whether they correlate with common prognostic factors and disease activity, we examined peripheral blood mononuclear cells (PBMC) from 70 patients with previously untreated CLL using an antibody to gamma-tubulin. All 70 CLL samples displayed significantly more cells with centrosome aberrations (median: 26.0%, range 11.0-41.5%) as compared to peripheral blood B lymphocytes from 20 age-matched, healthy individuals (median: 2.0%, range 0-6%; p < 0.001). The extent of centrosome aberrations correlated with the proliferative activity of the CLL cases as measured by lymphocyte doubling time (p = 0.02) as well as with time to first treatment (p = 0.05). Accordingly, more centrosome aberrations were found in PHA-stimulated T lymphocytes from healthy individuals as well as in B cells from surgically removed tonsil tissue of patients with acute tonsillitis as compared to the peripheral blood B lymphocytes from the control group. In contrast, no correlation was observed between centrosome aberrations and immunoglobulin VH gene mutation status or cytogenetically defined risk groups. These findings suggest that, despite the common observation of most CLL cells remaining in G(0)/G(1) phase, their centrosome replication process is deregulated and correlates to the proliferative activity of CLL cells. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17417785     DOI: 10.1002/ijc.22752

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Centrosome Aberration Frequency and Disease Association in B-Acute Lymphoblastic Leukemia.

Authors:  Lily S Kerketta; Kanjaksha Ghosh; Anita Nadkarni; Manisha Madkaikar; Babu Rao Vundinti
Journal:  In Vivo       Date:  2017 Mar-Apr       Impact factor: 2.155

Review 2.  CEP proteins: the knights of centrosome dynasty.

Authors:  Ambuj Kumar; Vidya Rajendran; Rao Sethumadhavan; Rituraj Purohit
Journal:  Protoplasma       Date:  2013-02-28       Impact factor: 3.356

Review 3.  Losing balance: the origin and impact of aneuploidy in cancer.

Authors:  Andrew J Holland; Don W Cleveland
Journal:  EMBO Rep       Date:  2012-06-01       Impact factor: 8.807

Review 4.  A clinical overview of centrosome amplification in human cancers.

Authors:  Jason Yongsheng Chan
Journal:  Int J Biol Sci       Date:  2011-10-16       Impact factor: 6.580

Review 5.  Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies.

Authors:  Karuna Mittal; Jaspreet Kaur; Meghan Jaczko; Guanhao Wei; Michael S Toss; Emad A Rakha; Emiel Adrianus Maria Janssen; Håvard Søiland; Omer Kucuk; Michelle Dian Reid; Meenakshi V Gupta; Ritu Aneja
Journal:  Cancer Metastasis Rev       Date:  2020-10-26       Impact factor: 9.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.